Jointown Pharmaceutical Group (600998) Q2 2025 earnings summary

Executive summary

• Achieved revenue of ¥81.11 billion, up 5.10% year-over-year; net profit attributable to shareholders rose 19.70% to ¥1.45 billion.

• Operating cash flow improved by ¥380 million year-over-year, driven by enhanced receivables collection.

• New business segments—pharmaceutical manufacturing and digital logistics—grew 10.77% and 24.66%, respectively.

• Completed the first public REITs issuance in the pharmaceutical logistics sector, adding ¥438 million to net profit.

• Continued investment in digitalization, AI, and talent, supporting strategic transformation.

Financial highlights

• Revenue: ¥81.11 billion, up 5.10% year-over-year.

• Net profit attributable to shareholders: ¥1.45 billion, up 19.70% year-over-year.

• Operating cash flow: -¥2.82 billion, improved by ¥380 million year-over-year.

• Gross margin: 7.54%; net margin: 1.78%.

• Adjusted net profit (excluding one-off impairment): ¥1.59 billion, up 31.44% year-over-year.

Outlook and guidance

• Management expects full-year operating cash flow to remain positive and aligned with business performance.

• Will continue to invest in new products, digitalization, and logistics asset securitization.

• Focus on expanding retail pharmacy network and digital healthcare services.